Literature DB >> 17043848

Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing.

Catherine S C Bouman1, Hendrikus J M van Kan, Richard P Koopmans, Johanna C Korevaar, Marcus J Schultz, Margreeth B Vroom.   

Abstract

OBJECTIVE: Drug dosing during continuous venovenous hemofiltration (CVVH) is based partly upon the CVVH clearance (Cl(CVVH)) of the drug. Cl(CVVH) is the product of the sieving coefficient (SC) and ultrafiltration rate (Q(uf)). Although it has been suggested that the SC can be replaced by the fraction of a drug not bound to protein (F(up)), the F(up) values as reported in the literature may not reflect the protein binding in critically ill patients with renal failure. We compared the observed Cl(CVVH) (SC x Q(uf)) with the estimated Cl(CVVH) (estimated F(UP) x Q(uf)) and determined the effect on the maintenance dose multiplication factor (MDMF). DESIGN AND
SETTING: Clinical study in a mixed ICU in a university hospital. PATIENTS: 45 oligoanuric patients on CVVH (2 l/h).
INTERVENTIONS: Timed blood and ultrafiltrate samples. MEASUREMENTS AND
RESULTS: Amoxicillin, ceftazidime, ciprofloxacin, fluconazole, metronidazole, and vancomycin were easily filtered (mean SC > 0.7) but not flucloxacillin (mean SC 0.3). Predicted and observed Cl(CVVH) corresponded only for fluconazole and metronidazole. The difference between observed and predicted MDMF was small for all drugs, with the exception of ceftazidime (mean 0.25, 95% CI -0.96 to 1.48) and vancomycin (0.05, -1.34 to 1.45). However, this difference was clinically relevant only for vancomycin, because of its narrow therapeutic index.
CONCLUSIONS: Dosing based on predicted CVVH removal provides an as reliable estimate than that based on observed CVVH removal except for those antibiotics that have both a narrow therapeutic index and a predominantly renal clearance (e.g., vancomycin).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17043848     DOI: 10.1007/s00134-006-0397-x

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  26 in total

Review 1.  Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage.

Authors:  J Böhler; J Donauer; F Keller
Journal:  Kidney Int Suppl       Date:  1999-11       Impact factor: 10.545

2.  Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients.

Authors:  Friederike Traunmüller; Peter Schenk; Christoph Mittermeyer; Renate Thalhammer-Scherrer; Klaus Ratheiser; Florian Thalhammer
Journal:  J Antimicrob Chemother       Date:  2002-01       Impact factor: 5.790

Review 3.  Drug dosing in acute renal failure: the role of renal replacement therapy in altering drug pharmacokinetics.

Authors:  R A Subach; M A Marx
Journal:  Adv Ren Replace Ther       Date:  1998-04

4.  Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients.

Authors:  R S Malone; D N Fish; E Abraham; I Teitelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  Determinants of drug removal by continuous hemofiltration.

Authors:  A H Lau; N O Kronfol
Journal:  Int J Artif Organs       Date:  1994-07       Impact factor: 1.595

6.  Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients.

Authors:  F T Boereboom; F F Ververs; P J Blankestijn; T J Savelkoul; A van Dijk
Journal:  Intensive Care Med       Date:  1999-10       Impact factor: 17.440

7.  Rapid removal of vancomycin by continuous veno-venous hemofiltration.

Authors:  M Shah; R Quigley
Journal:  Pediatr Nephrol       Date:  2000-09       Impact factor: 3.714

8.  Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis.

Authors:  G R Matzke; R F Frye; M S Joy; P M Palevsky
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

9.  Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure.

Authors:  M Valtonen; E Tiula; P J Neuvonen
Journal:  J Antimicrob Chemother       Date:  1997-11       Impact factor: 5.790

10.  Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration.

Authors:  Kazuaki Yagasaki; Satoshi Gando; Naoyuki Matsuda; Takashi Kameue; Toshiteru Ishitani; Takeshi Hirano; Ken Iseki
Journal:  Intensive Care Med       Date:  2003-09-13       Impact factor: 17.440

View more
  16 in total

1.  Presence and accuracy of drug dosage recommendations for continuous renal replacement therapy in tertiary drug information references.

Authors:  Sean K Gorman; Richard S Slavik; Stefanie Lam
Journal:  Can J Hosp Pharm       Date:  2012-05

Review 2.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy.

Authors:  Valentina Pistolesi; Santo Morabito; Francesca Di Mario; Giuseppe Regolisti; Chiara Cantarelli; Enrico Fiaccadori
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 4.  Renal replacement therapies: physiological review.

Authors:  Claudio Ronco; Zaccaria Ricci
Journal:  Intensive Care Med       Date:  2008-09-13       Impact factor: 17.440

5.  Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration.

Authors:  Takehito Yamamoto; Nobuhiro Yasuno; Shoichi Katada; Akihiro Hisaka; Norio Hanafusa; Eisei Noiri; Naoki Yahagi; Toshiro Fujita; Hiroshi Suzuki
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

Review 6.  Antibiotic dosing in critically ill patients with acute kidney injury.

Authors:  Rachel F Eyler; Bruce A Mueller
Journal:  Nat Rev Nephrol       Date:  2011-02-22       Impact factor: 28.314

7.  High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial.

Authors:  Olivier Joannes-Boyau; Patrick M Honoré; Paul Perez; Sean M Bagshaw; Hubert Grand; Jean-Luc Canivet; Antoine Dewitte; Claire Flamens; Wilfried Pujol; Anne-Sophie Grandoulier; Catherine Fleureau; Rita Jacobs; Christophe Broux; Hervé Floch; Olivier Branchard; Stephane Franck; Hadrien Rozé; Vincent Collin; Willem Boer; Joachim Calderon; Bernard Gauche; Herbert D Spapen; Gérard Janvier; Alexandre Ouattara
Journal:  Intensive Care Med       Date:  2013-06-06       Impact factor: 17.440

8.  Vancomycin therapy in critically ill patients on continuous renal replacement therapy; are we doing enough?

Authors:  Ali S Omrani; Alaa Mously; Marylie P Cabaluna; John Kawas; Mohammed M Albarrak; Wafa A Alfahad
Journal:  Saudi Pharm J       Date:  2014-09-07       Impact factor: 4.330

9.  Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.

Authors:  Fekade Bruck Sime; Michael S Roberts; Sandra L Peake; Jeffrey Lipman; Jason A Roberts
Journal:  Ann Intensive Care       Date:  2012-07-28       Impact factor: 6.925

10.  Clinical Validation of Therapeutic Drug Monitoring of Imipenem in Spent Effluent in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot Study.

Authors:  Aiping Wen; Zhe Li; Junxian Yu; Ren Li; Sheng Cheng; Meili Duan; Jing Bai
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.